Perioral Dermatitis

Perioral dermatitis (POD) is an inflammatory papulopustular eruption around the mouth, nose, and eyes — predominantly affecting young women — that is strongly associated with topical corticosteroid use and is treated by stopping all steroids and using topical or oral antibiotics.

Table of Contents

  1. Epidemiology and Risk Factors
  2. Pathogenesis
  3. Clinical Features
  4. Diagnosis
  5. Treatment: Steroid Withdrawal
  6. Treatment: Topical Therapies
  7. Treatment: Oral Antibiotics
  8. Granulomatous Perioral Dermatitis
  9. Key Research Papers
  10. PubMed Searches
  11. Connections
  12. Featured Videos

1. Epidemiology and Risk Factors

Perioral dermatitis is a common inflammatory skin condition seen worldwide, with an estimated prevalence of 0.5–1% in dermatology populations. It predominantly affects young women between the ages of 16 and 45, with a female-to-male ratio of 5–10:1. While men and children can develop POD, peak incidence occurs among reproductive-age women — a pattern that has led researchers to investigate hormonal contributions to disease pathogenesis.

The single most important and well-documented trigger is topical corticosteroid (TCS) use. Fluorinated corticosteroids — including triamcinolone, fluocinonide, and clobetasol — carry a higher risk than non-fluorinated preparations, but prolonged or repetitive application of any potency class, including over-the-counter hydrocortisone, can precipitate or perpetuate POD. Intranasal corticosteroid sprays and inhaled steroids (whose swallowed particles contact the perioral skin) are also implicated, particularly when use is chronic.

Secondary triggers include:

A familial tendency has been observed in some case series, suggesting a genetic predisposition to inflammatory skin reactivity. Notably, the COVID-19 pandemic era brought a documented surge in POD cases, attributed to both increased mask-wearing (creating a warm, occlusive perioral microenvironment) and increased topical corticosteroid use for mask-related irritant dermatitis — a cycle that reinforced and worsened underlying POD in many patients.

↑ Back to Table of Contents

2. Pathogenesis

The exact pathogenesis of perioral dermatitis remains incompletely understood, but current evidence points to a multifactorial process involving skin barrier disruption, microbiome dysbiosis, and an aberrant inflammatory response — often initiated or perpetuated by topical corticosteroid use.

Skin barrier disruption: Topical corticosteroids thin the epidermis through suppression of keratinocyte proliferation and collagen synthesis. Chronic application reduces ceramide production and disrupts the intercellular lipid matrix of the stratum corneum, impairing barrier integrity. This creates a permeable perioral environment susceptible to colonization by commensal and pathogenic microorganisms.

Microbiome dysbiosis: Several organisms have been implicated in POD pathogenesis. Fusiform bacteria (Fusobacterium species) have been identified in lesional biopsies in some studies. Demodex folliculorum mites are found at increased density in POD lesions compared to normal perioral skin, and their role — either as direct triggers of inflammation or secondary colonizers taking advantage of a disrupted barrier — remains debated. Candida species may contribute in some patients, particularly those who have used topical corticosteroids extensively.

The steroid paradox: Topical corticosteroids initially suppress the redness and irritation of early POD, providing apparent relief. This encourages continued or escalating use, further disrupting the skin barrier and altering the local immune environment. When the steroid is withdrawn, a pronounced rebound flare occurs — erythema intensifies, lesions multiply, and burning worsens — mimicking a severe inflammatory episode and compelling many patients to restart topical steroids. This self-perpetuating cycle is central to the chronicity of steroid-induced POD.

Fluoride hypothesis: Sodium fluoride in toothpaste may elicit a perioral inflammatory reaction in susceptible individuals. The mechanism is believed to involve direct irritation of the follicular epithelium and perifollicular connective tissue. Switching to non-fluoride toothpaste is a standard recommendation and benefits many patients, though it is not universally effective, suggesting that fluoride sensitivity is one contributing factor rather than the sole cause.

Occlusive cosmetics: Heavy emollients and occlusive cosmetics can obstruct pilosebaceous units around the mouth, creating a comedone-like plugging effect that initiates papule formation — a mechanism similar to acne mechanica. The occlusive environment also promotes bacterial overgrowth within follicular units.

Hormonal contribution: The strong female predominance and the clinical observation that POD frequently worsens premenstrually and may develop or exacerbate with oral contraceptive use suggest that sex hormones influence sebaceous gland activity and local inflammatory pathways — possibly through androgen receptor modulation of sebocyte proliferation and lipid production.

↑ Back to Table of Contents

3. Clinical Features

Perioral dermatitis has a characteristic distribution and morphology that distinguish it from other common facial dermatoses. The term periorificial dermatitis is increasingly preferred, as the eruption affects three orificial areas: perioral (most common), perinasal, and periocular.

Distribution: The chin and upper lip area are most commonly affected, followed by the nasolabial folds. Perinasal involvement produces a similar papulopustular pattern flanking the nostrils. Periocular (periorbital) POD — affecting the skin around the eyelids — may occur in isolation or together with perioral lesions and is especially common in children. Bilateral but asymmetric involvement is typical.

The pathognomonic hallmark of POD is sparing of the vermilion border — a 1–3 mm pale ring of clinically normal skin immediately adjacent to the lip margin. This characteristic sparing reliably distinguishes POD from acne vulgaris (which has no predilection for the perioral zone) and from rosacea (which involves the central face but not in this specific perioral-sparing pattern).

Lesion morphology: The primary lesions are erythematous papules measuring 1–3 mm in diameter, often with superimposed micropustules. The lesions are non-comedonal — there are no blackheads or whiteheads (comedones), which is a critical distinguishing feature from acne. Papules cluster in groups on an erythematous background, giving the skin a rough, bumpy texture.

Scaling and texture: Fine scaling is common, and patients frequently report that affected skin feels tight, dry, and uncomfortable. Unlike the greasy scale of seborrhoeic dermatitis, the scale in POD is dry and superficial.

Symptoms: Mild burning, stinging, or itching is frequently reported. Some patients experience only cosmetic concerns without significant discomfort. The condition is not typically painful. Psychological distress related to the facial location of the eruption is common and should not be underestimated.

Natural history without treatment: Untreated POD follows a chronic, waxing-and-waning course. In patients continuing topical corticosteroid use, the condition typically worsens over months to years. Spontaneous remission can occur but may take many months. Relapses are common, particularly if the precipitating factors (steroid use, heavy cosmetics, fluoride toothpaste) are not addressed.

↑ Back to Table of Contents

4. Diagnosis

Perioral dermatitis is a clinical diagnosis, established by recognizing the characteristic distribution (perioral, perinasal, or periocular), the pathognomonic sparing of the vermilion border, the non-comedonal papulopustular morphology, and a history of topical corticosteroid use or other recognized triggers. No laboratory tests or imaging are required for the diagnosis in typical cases.

Skin biopsy is reserved for atypical presentations or when the diagnosis is uncertain. Histopathological findings include a perifollicular and subepidermal lymphohistiocytic infiltrate, spongiosis, sebaceous gland dilation, and variable degrees of epidermal disruption. Non-caseating granulomas are the defining feature of the granulomatous variant. Biopsy does not show the caseating necrosis of cutaneous tuberculosis or the elastolytic changes of granuloma annulare.

The differential diagnosis includes several important conditions:

↑ Back to Table of Contents

5. Treatment: Steroid Withdrawal

The single most important step in managing perioral dermatitis is stopping all topical corticosteroids. This is non-negotiable — continuing even a low-potency preparation will perpetuate the cycle of barrier disruption and inflammatory rebound that drives the disease. The cessation must include:

The steroid withdrawal phenomenon is the most critical concept for patient counseling. Within 2–3 weeks of stopping topical corticosteroids, erythema worsens, lesions multiply, burning and stinging intensify, and the overall appearance deteriorates significantly. This rebound flare is expected and temporary — it is not a sign of treatment failure or disease progression. Without adequate preparation for this rebound, the majority of patients will restart their topical steroid at this point, perpetuating the cycle indefinitely.

Patient counseling before initiating steroid withdrawal should be detailed and empathetic:

  1. Explain that the skin will worsen significantly for 2–4 weeks before improving
  2. Reassure that this worsening is a predictable pharmacological rebound, not allergy or infection
  3. Provide specific timelines: peak rebound at 2–4 weeks; beginning of improvement at 4–8 weeks; expected resolution at 8–12 weeks with appropriate treatment
  4. Instruct the patient to contact the clinic if symptoms are severe rather than restarting steroids independently
  5. Provide written information to reinforce verbal counseling

Some dermatologists advocate a "zero therapy" approach in the first 2–4 weeks: stopping not only all topical corticosteroids but also all cosmetics, moisturizers, and non-essential topical products. This complete elimination of potential irritants and occlusive agents allows the skin barrier to begin recovering without interference. While initially uncomfortable, zero therapy accelerates the restoration of normal perioral skin physiology.

Simultaneously, patients should be advised to switch to a non-fluoridated toothpaste and to avoid heavy, occlusive moisturizers and cosmetics for the duration of treatment.

↑ Back to Table of Contents

6. Treatment: Topical Therapies

Topical therapies are the foundation of treatment for mild-to-moderate perioral dermatitis and are used as adjuncts to oral antibiotics in more severe cases. They are applied after stopping all topical corticosteroids and should be continued for 8–12 weeks for full effect.

Metronidazole 0.75–1% gel or cream is the first-line topical agent for perioral dermatitis. Applied twice daily to affected areas, metronidazole exerts both antimicrobial effects (against anaerobic bacteria and Demodex mites) and direct anti-inflammatory effects through inhibition of reactive oxygen species and cytokine production. It is well tolerated, with minimal systemic absorption and a favorable safety profile for prolonged use. Mild initial stinging or dryness is common but usually transient.

Erythromycin 2% gel is an alternative topical antibiotic useful when metronidazole is unavailable, not tolerated, or in patients with a history of sensitivity. Applied twice daily, it provides antimicrobial coverage with some anti-inflammatory benefit. Increasing bacterial resistance to erythromycin means it is generally considered second-line to metronidazole.

Azelaic acid 15–20% gel or cream offers a valuable dual mechanism: it is both antimicrobial (including activity against Demodex and anaerobes) and directly anti-inflammatory through inhibition of reactive oxygen species. It is particularly useful in patients with overlapping POD and rosacea. Applied twice daily, azelaic acid causes mild stinging and transient skin irritation in the first 1–2 weeks of use, which typically resolves. It has an excellent long-term safety profile and is safe in pregnancy.

Pimecrolimus 1% cream (Elidel) is a calcineurin inhibitor that reduces perifollicular and dermal inflammation without the atrophogenic effects of topical corticosteroids. It is particularly effective for steroid-induced POD and for patients in whom the barrier is severely compromised by prior corticosteroid use. Applied twice daily, it does not cause skin thinning or telangiectasia formation. Initial mild burning is common. It is especially useful for periocular POD where thin eyelid skin makes other topicals poorly tolerated.

Tacrolimus 0.03–0.1% ointment has a similar mechanism to pimecrolimus and may be more effective in refractory cases. The 0.03% concentration is preferred in children; the 0.1% formulation is available for adults with refractory disease.

Clindamycin 1% lotion or gel is widely used as a topical antibiotic for POD, though clinical evidence is less robust than for metronidazole. Applied twice daily, it is a reasonable alternative, particularly for patients with mild disease or when other agents are not available.

Adjunctive measures during topical therapy:

↑ Back to Table of Contents

7. Treatment: Oral Antibiotics

Oral antibiotics are indicated for moderate-to-severe perioral dermatitis, widespread facial involvement, cases that have failed to respond adequately to topical therapy alone, and the granulomatous variant. They are often combined with topical agents (particularly metronidazole gel) for faster and more complete resolution.

Tetracyclines — first-line in adults:

Doxycycline at 50–100 mg/day for 8–12 weeks is the most widely used oral agent for POD. Its therapeutic benefit in POD — as in rosacea — operates primarily through anti-inflammatory mechanisms rather than purely antimicrobial ones: doxycycline inhibits matrix metalloproteinases (MMPs), suppresses pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha), and reduces reactive oxygen species production by neutrophils. A sub-antimicrobial dose of 40 mg/day (modified-release formulation) is effective in some patients and minimizes resistance pressure. Doxycycline should be taken with food and a full glass of water to reduce esophageal irritation. Photosensitivity is a clinically important side effect; patients should use sun protection. Doxycycline is contraindicated in pregnancy and in children under 8 years (risk of permanent tooth staining and impaired bone growth).

Minocycline at 50–100 mg/day is an alternative tetracycline. It is more lipophilic than doxycycline and achieves higher tissue concentrations in skin. However, it carries a higher risk of blue-grey hyperpigmentation with prolonged use (minocycline-induced pigmentation), vestibular side effects (dizziness, vertigo), and rare but serious drug reactions (drug-induced lupus, autoimmune hepatitis). For these reasons, minocycline is generally considered second-line to doxycycline.

Erythromycin at 250–500 mg twice daily for 8–12 weeks is the preferred oral antibiotic for pregnant women and children under 8 years, in whom tetracyclines are contraindicated. Gastrointestinal side effects (nausea, cramping, diarrhea) are common and may limit adherence. Erythromycin is generally less effective than tetracyclines in adults but is a clinically important alternative when tetracyclines cannot be used.

Tapering rather than abrupt discontinuation of oral antibiotics at the end of the course is prudent to reduce the risk of rebound flare. A gradual dose reduction over 2–4 weeks is preferred to abrupt cessation.

Isotretinoin (low-dose) is reserved for refractory perioral dermatitis that has failed multiple courses of conventional therapy, and for the granulomatous variant. Doses of 0.2–0.5 mg/kg/day for 4–6 months are typically effective. Standard isotretinoin precautions apply: it is a potent teratogen requiring strict contraception and iPLEDGE program enrollment in the United States; monthly liver function and lipid monitoring; and screening for depression and mood changes. Despite these requirements, low-dose isotretinoin is highly effective for refractory POD and offers the prospect of long-term remission.

Practical combination approach: For moderate-to-severe POD, initiating oral doxycycline together with topical metronidazole gel at the time of steroid cessation provides the fastest response and highest rate of complete clearance. Topical therapy is continued throughout the oral antibiotic course and for 4–8 weeks after oral antibiotics are discontinued.

↑ Back to Table of Contents

8. Granulomatous Perioral Dermatitis

Granulomatous perioral dermatitis is a rare but clinically distinct variant of POD characterized by firm, indurated papules with histological evidence of non-caseating granulomas. In children, this variant is known as facial Afro-Caribbean childhood eruption (FACE), though it occurs in children of all ethnicities and racial backgrounds.

Epidemiology: Granulomatous POD primarily affects prepubertal children, with a roughly equal sex distribution — in contrast to the strong female predominance of classic adult POD. Adult cases occur but are less common. The condition may affect any race or ethnicity.

Clinical features: The lesions are firm, indurated papules 1–4 mm in diameter, appearing skin-colored to yellow-brown. Unlike classic POD, which features erythematous micropustules, granulomatous POD papules are more solid and dome-shaped. Diascopy (pressing a glass slide against the lesion) reveals the characteristic yellowish-brown "apple-jelly" translucency typical of granulomatous inflammation. Lesions cluster around the perioral, perinasal, and periocular zones — the same distribution as classic POD. The vermilion border sparing is typically preserved.

Corticosteroid history: Unlike adult POD, many children with granulomatous POD have no history of prior topical corticosteroid use. This suggests that other factors — possibly infectious or immunological — drive granuloma formation in some cases. However, steroid-exposed cases do occur in this variant as well.

Histopathology: Biopsy shows perifollicular non-caseating granulomas with lymphohistiocytic infiltrates and foreign body giant cells. The absence of caseating necrosis distinguishes granulomatous POD from cutaneous tuberculosis (lupus vulgaris) — a critical distinction, particularly in high-prevalence TB regions. The granulomas are typically perifollicular, centred on the hair follicle unit.

Differential diagnosis:

Treatment: Low-dose oral erythromycin (for children) or azithromycin is the preferred first-line treatment for granulomatous POD. Topical metronidazole gel may provide adjunctive benefit. The condition may undergo spontaneous resolution over months to years, particularly in children. For adult granulomatous POD resistant to antibiotics, low-dose oral isotretinoin has demonstrated efficacy and is the preferred second-line option.

↑ Back to Table of Contents

9. Key Research Papers

  1. Dirschka T, et al. "Perioral dermatitis." J Dtsch Dermatol Ges. 2015;13(2):102–108. PMID 25692678 — Comprehensive German dermatology society review covering epidemiology, pathogenesis, clinical features, and treatment guidelines.
  2. Nguyen V, Eichenfield LF. "Periorificial dermatitis in children and adolescents." J Am Acad Dermatol. 2006;55(5):781–785. PMID 17052484 — Characterizes clinical features and treatment outcomes in pediatric periorificial dermatitis, including the granulomatous variant (FACE).
  3. Hafeez ZH. "Perioral dermatitis: an update." Int J Dermatol. 2003;42(7):514–517. PMID 12839597 — Review of pathogenic theories, clinical variants, and treatment approaches including metronidazole and tetracyclines.
  4. Wollenberg A, et al. "Perioral dermatitis." J Dtsch Dermatol Ges. 2019;17(12):1255–1264. PMID 31808310 — Updated evidence-based review with current diagnostic criteria and management recommendations, including calcineurin inhibitors.
  5. Veenstra AJ, et al. "Metronidazole in the treatment of perioral dermatitis." J Eur Acad Dermatol Venereol. — PubMed Search — Clinical evidence supporting metronidazole gel as a first-line topical agent for POD.
  6. Schwarz T, et al. "Granulomatous perioral dermatitis in children." J Am Acad Dermatol. 1991;25(1):7–9. PMID 1869712 — Early characterization of granulomatous POD (FACE) in the pediatric population, establishing non-caseating granulomas as the histological hallmark.
  7. Cotterill JA. "Perioral dermatitis." Br J Dermatol. 1979;101(3):259–262. PMID 497681 — Classic paper documenting the vermilion border sparing sign and the association with topical corticosteroid use; foundational clinical description.
  8. Hoting E, et al. "Pimecrolimus cream 1% in the treatment of perioral dermatitis." J Eur Acad Dermatol Venereol. 2007;21(10):1349–1354. PMID 17958839 — Randomized controlled trial demonstrating efficacy of pimecrolimus 1% cream for POD, providing evidence for calcineurin inhibitors as steroid-free alternatives.
  9. Lipozencic J, et al. "Perioral dermatitis." Clin Dermatol. 2011;29(2):157–161. PMID 21396558 — Clinical dermatology review covering etiology, differential diagnosis, and treatment options with a focus on practical management.
  10. Tempark T, Shwayder TA. "Perioral dermatitis: a review of the condition with special attention to treatment options." Am J Clin Dermatol. 2014;15(2):101–113. PMID 24481999 — Systematic review of treatment modalities including topical metronidazole, azelaic acid, pimecrolimus, tetracyclines, and isotretinoin; highlights steroid withdrawal as the essential first step.
  11. Schader I, Wollenberg A. "Topical pimecrolimus for the treatment of steroid-induced perioral dermatitis." Acta Derm Venereol. 2012;92(5):523–524. PMID 22173480 — Case series supporting pimecrolimus as a steroid-sparing treatment specifically for TCS-induced POD, with discussion of the withdrawal phenomenon.
  12. Pasternack FR, et al. "Perioral dermatitis — is the skin barrier impaired?" Exp Dermatol. 2009;18(3):218–223. PMID 19292762 — Investigates transepidermal water loss and barrier function in POD lesional vs. non-lesional skin, providing mechanistic evidence for barrier disruption as a pathogenic factor.

↑ Back to Table of Contents

10. PubMed Searches

  1. Perioral dermatitis treatment
  2. Perioral dermatitis and topical corticosteroids
  3. Periorificial dermatitis in children
  4. Perioral dermatitis metronidazole
  5. Perioral dermatitis doxycycline

↑ Back to Table of Contents

11. Connections

↑ Back to Table of Contents